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Abstract: Ulcerative colitis (UC) is an immune-mediated disease of the colon that is characterized by diffuse and continuous inflammation contiguous from the rectum. Half of UC patients
have inflammation limited to the distal colon (proctitis or proctosigmoiditis) that primarily
causes symptoms of bloody diarrhea and urgency. Mild-to-moderate distal UC can be effectively
treated with topical formulations (rectal suppositories, enemas, or foam) of mesalamine or
steroids to reduce mucosal inflammation and alleviate symptoms. Enemas or foam formulations
adequately reach up to the splenic flexure, have a minimal side-effect p rofile, and induce remission alone or in combination with systemic immunosuppressive therapy. Herein, we compare
the efficacy, cost, patient tolerance, and side-effect profiles of steroid and mesalamine rectal
formulations in distal UC. Patients with distal mild-to-moderate UC have a remission rate of
approximately 75% (NNT =2) after treatment for 6 weeks with mesalamine enemas. Rectal
budesonide foam induces remission in 41.2% of patients with mild-to-moderate active distal
UC compared to 24% of patient treated with placebo (NNT =5). However, rectal budesonide
has better patient tolerance profile compared to enema formulations. Despite its favorable
efficacy, safety, and cost profiles, patients and physicians significantly underuse topical treatments for treating distal colitis. This necessitates improved patient education and physician
familiarity regarding the indications, effectiveness, and potential financial and tolerability
barriers in using rectal formulations.
Keywords: inflammatory bowel disease, treatment cost effectiveness, Crohn’s disease,
ulcerative colitis, colon mucosa, proctitis suppositories, topical immunosuppressive therapy
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Inflammatory bowel disease (IBD) is a chronic immune-mediated disease of the
gastrointestinal tract that affects more that 1.6 million Americans.1,2 Ulcerative colitis
(UC) is characterized by diffuse, continuous, superficial, and ulcerating inflammation
confined to the colon that causes rectal bleeding, diarrhea, and abdominal pain. The
current working model of IBD pathogenesis posits a dysregulated immune response
against gut microbiota in the presence of genetic defects, leading to exaggerated selfinjurious inflammatory responses. Genome-wide association studies have identified
IBD susceptibility genes, the majority of which are immunoregulatory.3,4 UC can
have varied distribution and severity. Ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS), defined as disease extending 15 and 40 cm from the anal verge,
respectively, are seen in approximately 50% of UC patients.5 Left-sided colitis, seen
in around 30% of UC patients, involves continues inflammation from the anus to the
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splenic flexure, and only 20% of UC patients have extensive
colitis or pancolitis.6
The mainstay therapy for IBD involves anti-inflammatory
immunosuppression dictated by the severity and location of
disease. Moderate-to-severe disease is typically treated with
immunosuppressive medications such as azathioprine, antiTNFα, and more recently, anti-integrin agents.7 Oral corticosteroids are limited to treating acute flares and have limited
efficacy in maintaining remission.8 Rectally administered
therapies can be effective in distal colitis and include suppositories for proctitis or enemas and foam preparations for
proctosigmoiditis and left-sided colitis. However, because of
lack of knowledge and familiarity regarding efficacy, safety,
and patient tolerance, topical therapies are often underused in
UC patients. The Swiss Inflammatory Bowel Disease Cohort
study reports that only 26% of patients with mild-to-moderate
proctitis were treated with topical therapy and only 13% of
patients with active extensive colitis received treatment that
included topical rectal therapy.9
Herein, we provide an updated literature review of the
effectiveness, safety, tolerability, and cost of topical treatments for distal inflammatory colitis. We compare different
formulations of topical therapies (ie, suppositories, enemas,
and rectal foam) with a particular focus on how budesonide, a
specific corticosteroid, compares to other treatments. Importantly, we provide a framework and treatment algorithm for
distal UC.

Available topical therapies for
distal colitis
Common therapies for the treatment of UP and UPS include
5-aminosalicylic acid (5-ASA) and steroids. Mesalamine and
other 5-ASA substances are the first-line choice in treating
mild-to-moderate UC, regardless of the physical extent of
disease. Mesalamine has multiple reported anti-inflammatory
effects that include inhibiting leukotriene and IL-1 production, impairing TNFα and NF-κB transcription signaling
and having antioxidant properties by acting as a free-radical
scavenger.10 Additionally, mesalamine reduces mucosal
inflammation by acting on mucosal colonic epithelial cells
and infiltrating leukocytes, with its clinical efficacy therefore
correlating with its local concentration in the gut.
Oral mesalamine is effective and can induce remission
in active UC; however, delivery of the active agent to the
inflamed distal colon is limited. Intolerance to the sulfapyridine moiety of sulfasalazine is fairly common and may result
in nausea, vomiting, dyspepsia, anorexia, and headache. More
severe but less common adverse effects for sulfasalazine
and melamine oral formulations include allergic reactions,
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pancreatitis, hepatotoxicity, drug-induced connective tissue
disease, bone marrow suppression, interstitial nephritis, and
hemolytic anemia or megaloblastic anemia.11 In a multicenter,
double-blind study, patients with mild-to-moderate active
UC were randomized to either oral mesalamine or placebo
and were followed at 3- and 6-week time points. At 3 weeks,
remission rates (defined by improved stool frequency, rectal bleeding, and sigmoidoscopic findings) were 32% for
patients treated with 2.4 g/d of mesalamine vs 9% in the
placebo arm, and at 6 weeks, efficacy increased to 49% vs
23%, respectively.12 However, in mild-to-moderate UP and
UPS, topically administered 5-ASA (ie, suppository, enema,
or rectal foam preparations) can be more efficacious both
at generating a response and inducing remission than oral
5-ASA. A randomized, double-blinded trial demonstrated
endoscopic remission and decreased rectal bleeding in
patients with mild-to-moderate UC with rectal inflammation
after a 4-week treatment period with 1 g mesalazine suppository once daily as compared to placebo (81.5% vs 29.7%,
P<0.0001).13 However, suppositories rarely extend beyond
10–15 cm from the rectum, making them less attractive as a
rectal formulation. A meta-analysis comparing rectal 5-ASA
to placebo in patients with distal UC demonstrated that rectal
5-ASA was superior to placebo for inducing symptomatic
remission (OR: 8.3, 95% CI: 4.3–16.1) and endoscopic
remission (OR: 5.3, 95% CI: 3.2–8.9).14
Practice guidelines recommend using topical mesalamine
agents as first line compared to topical steroids or oral aminosalicylates for the treatment of distal mild-to-moderate
UC, and the combination of oral and topical aminosalicylates
is more effective than either alone. 15 In addition, practice
guidelines recommend mesalamine suppositories or enemas
as the preferred agents to maintain remission in distal mild-tomoderate UC. Mesalamine suppositories maintain remission
in 90% of patients with mild-to-moderate UP at 1 year, while
mesalamine enemas maintain remission in 72% of patients
with mild-to-moderate UPS when administered every other
day at 1 year.16,17
Topical steroids are an alternative treatment for distal
colitis, particularly if patients fail or do not tolerate 5-ASA
therapy. They have long-ranging anti-inflammatory effects
through various mechanisms, including expression of antiinflammatory cytokine IL-10, inhibition of histone acetylation
and immune cell apoptosis, and reduced signaling of inflammatory transcription factors such as NF-kB and AP-1. Oral corticosteroids are efficacious in controlling acute colitis flares, but
16% of patients show no response and 30% show only a partial
response.8 Moreover, oral steroid use can have numerous side
effects, spanning multiple organ systems: acne, moon facies,
Clinical and Experimental Gastroenterology 2016:9
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infection, hypertension, and hirsutism being among the most
common. Notable effects from long-term corticosteroid use are
hypertension, diabetes, adrenal insufficiency, osteoporosis, and
psychosis.18 Given the side-effect profile, oral steroid therapy is
limited to short-treatment intervals in patients with moderateto-severe disease rather than long-term maintenance.16 Rectally
applied steroids offer advantages as compared to orally administered drugs because they offer a more targeted treatment to
the areas of active inflammation and generally have fewer
systemic effects than oral corticosteroid use.19,20 Budesonide
is a lipophilic agent with lower systemic bioavailability, which
can potentially cause lower systemic side effects.

Efficacy of budesonide rectal foam
Budesonide, a high-potency, nonhalogenated, second-generation corticosteroid, can be used either topically or orally in
patients with UC. The pharmacokinetic profile of budesonide
rectal foam, specifically the extent of spread and length of
persistence in the colon, make it an efficacious topical treatment. Using [99Tcm]-labeled budesonide foam in patients with
moderate proctosigmoiditis or left-sided colitis, Brunner et al21
determined that budesonide spread 25.4±10.3 cm, reached

the sigmoid colon in all patients, and had a mean colonic
residence time of 5.3 hours. Sandborn et al19 compared rectal
budesonide foam to placebo in two randomized, double-blind,
side-by-side trials utilizing 546 patients with mild-to-moderate
UP or UPS. All patients had disease extending at least 5 cm,
but no >40 cm from the anal verge. The budesonide treatment
arm received 2 mg/mL two times daily (BID) dosing of the
foam for 2 weeks and then was switched to once daily dosing
for 4 weeks. The primary end point was remission, defined
by Mayo Score ≤1, no rectal bleeding, and either no change
or an improvement in stool frequency. A combined 41.2%
of patients demonstrated remission as compared to 24% of
the placebo patients (P<0.0001). Interestingly, in subgroup
analysis, budesonide rectal foam was still superior to placebo
regardless of concurrent use of <4.8 g/d of oral mesalamine,
suggesting that budesonide foam can have additive treatment
effects in patients already receiving oral mesalamine treatment.
Comparison of budesonide with other corticosteroid rectal foam therapies, however, did not demonstrate increase in
efficacy (Table 1). Bar-Meir et al20 investigated the differences
between budesonide and hydrocortisone administration as
rectal foam. This randomized, parallel-group, multicenter

Table 1 Comparison of important clinical trials of melamine or steroid topical formulations to treat mild-to-moderate UC
Treatment

Remission rates

Oral
mesalamine vs
placebo

At 6 weeks, with 1.6 g/d: 38% >40 cm
43% vs 23% (P=0.03)
44% 20–40 cm
At 6 weeks, with 2.4 g/d: 17% <20 cm
49% vs 23% (P=0.003)

Mesalamine
suppository vs
placebo

Endoscopic remission:
82% vs 30% (P<0.0001)
Clinical remission: 63%
vs 17% (P<0.0001)

11% pancolitis
Rectal suppository
4% left-sided colitis once daily
13% sigmoiditis
67% proctitis

4

Endoscopic remission: scores of 0 or 13
1 at the site of rectal inflammation
Clinical remission: UC-DAI score
≤2 and bleeding score of 0

Mesalamine
enema vs
budesonide
enema

77% vs 64% (P<0.05)

37.7% left colitis
58.1%
proctosigmoiditis
4.2% proctitis

Mesalamine enema
(4 g/60 mL)
Budesonide enema
(2 mg/100 mL)

8

Improvement in clinical disease
activity score, endoscopic index
score, and IBDQ

28

Budesonide
foam vs
placeboa

41% vs 24% (P<0.0001)

72%
proctosigmoiditis
28% proctitis

2 mg/mL BID ×
2 weeks,
then 2 mg/mL
daily × 4 weeks

6

Endoscopy subscore ≤1, rectal
bleeding subscore of 0, and
improvement or no change from
baseline in the stool frequency
subscore of the Mayo score

19

67.3%
proctosigmoiditis
32.7% proctitis

Budesonide foam
8
(2 mg/20 mL) once
nightly
Hydrocortisone
foam (100 mg/
15 mL) once nightly

Defined by a disease activity index
score of 3 or less

20

53% vs 52%
Budesonide
(P not significant)
foam vs
hydrocortisone
foama

Site of study

Frequency and
Follow-up Remission criteria
length of therapy (weeks)

References

1.6 g/d vs 2.4 g/d of 6
mesalamine

12

Scores for stool frequency, rectal
bleeding, functional assessment,
sigmoidoscopic findings, global
assessment

Note: aConcomitant use of oral mesalamine at a stable dosage of up to 2 g/d was permitted.
Abbreviations: BID, two times daily; UC, ulcerative colitis; CAI, clinical disease activity; EI, endoscopic index; IBDQ, inflammatory bowel disease questionnaire; DAI, disease
activity index.
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clinical trial included 251 patients with active mild-tomoderate UPS and demonstrated similar efficacy (remission
rates of approximately 50%) following a 6-week treatment
period with either steroid rectal foam. Thus, for patients with
distal UC, hydrocortisone or budesonide rectal foam can be
an efficacious therapeutic choice.

Patient safety, tolerance, and use of
budesonide rectal foam
Multiple studies have shown that budesonide foam is safe
for administration in UP and UPS, with minimal adverse
effects and rare serious adverse effects. These adverse
events are thought to be secondary to intestinal absorption of budesonide.21 The most common adverse effects
include headache, nausea, decreased serum cortisol levels,
and abdominal pain.18 In the randomized, side-by-side trial
by Sandborn et al,19 serious adverse events occurred in
1%–2% of patients, rates that were not significantly higher
than placebo and had no clear association with budesonide.
Budesonide can cause transient decrease in cortisol levels
in 16% of patients when administered as a BID dosing for
2 weeks. However, by the end of the 6-week trial, 94.2% of all
patients in the budesonide treatment arm had normal cortisol
levels. Altogether, the data support the fact that budesonide
rectal foam is a safe treatment with minimal adverse events
associated with its use.
Rectal foam formulations have been designed to provide
a more uniform delivery to the left colon and to optimize
retention. One advantage in using foam as opposed to
enemas is the sheer volume of therapy (20–25 mL for foam
vs 60–100 mL for enema). Because of the higher volume,
urgency and abdominal/rectal discomfort tend to be more
associated with enemas. A recent double-blind, doubledummy randomized trial by Gross et al22 compared remission
rates and overall patient tolerability/satisfaction between
budesonide enemas vs foam in the treatment of active UP or
UPS. The study highlighted that though the overall remission
rates were similar between the two treatment modalities (66%
for enema vs 60% for foam), there was an overwhelming
preference for the foam formulation (84%). This disparity in
patient preference/satisfaction was due in part to higher rates
of retention while using enemas as opposed to foam (39%
compared to 11%, respectively), more unpleasant feelings
(36% compared to 12%, respectively), and more rectal pain
(18% compared to 10%, respectively).
Instructions to patients should include the importance
of emptying bowels before administering the rectal foam
and stress lubrication of the applicator. Patients should be
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advised to warm the canister in their hands while shaking
it vigorously for 10–15 seconds prior to use and that application of the rectal foam can be done while in a standing,
lying, or sitting position. Additionally, application of rectal
foam should be performed in the morning and before bed
the first 2 weeks of treatment, and then once daily in the
evening for the next 4 weeks. Budesonide is metabolized via
CYP3A4, and therefore, patients should be advised to avoid
ketoconazole or grapefruit juice during treatment to prevent
increased exposure.

Available formulations and cost of topical
therapies
Both ASA and steroids come in different formulations,
including suppositories, enemas, and more recently, foams.
Efficacies and costs of these various formulations are summarized in Table 1. The extent and severity of UC and treatment response and duration among different study patient
populations varied; therefore, direct comparisons of efficacy
and overall health care cost among the different medications
have to be done in relative terms. The extent and severity of
the colonic inflammation dictates the formulation of topical
therapy. Suppositories are more commonly used in mildto-moderate cases of proctitis, while enemas and foams are
typically used in more extensive disease, such as proctosigmoiditis and left-sided colitis. Immunomodulator treatment
is often used in moderate-to-severe UC or mild-to-moderate
disease that had minimal response to mesalamine formulations. Topical therapy in combination with immunomodulatory treatment provided further symptoms control in patients
with active distal colitis.15
In the United States, the price of topical, oral, and parenteral biologic therapy for IBD varies and ranges from <$100
per month for sulfasalazine and azathioprine to several
thousand dollars for biologic therapy (Table 2). Budesonide
rectal foam is sold in kits that contain a canister of 33.4 g and
applicators that deliver 14 2 mg doses. A 6-week course of
budesonide foam is generally recommended to induce remission, with twice-daily dosing for the first 2 weeks, followed
by once-a-day dosing for the remaining 4 weeks. Each of
the budesonide foam kits costs approximately $320, making
the recommended 6 week course cost $1,280. Mesalamine
suppositories and enemas despite being on the market for
decades cost $1,000–$1,600 per month when used once daily.
Furthermore, an 80 kg person receiving 5 mg/kg of infliximab
generates a drug cost of almost $47,000 in the first year of
treatment.23 Similarly, vedolizumab, a gut-selective blockade of lymphocyte trafficking, is administered in 300 mg
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Table 2 Comparative efficacy and cost of topical and other immunosuppressive treatments for distal UC
Active drug

Formulation

Trade name

Dose

Efficacy NNT

Price ($/month)

References

5-ASA

Suppository
Enema
Oral
Oral/delayed release
Suppository
Enema
Foam
Foam
Oral
Oral
Infusion
Infusion

Canasa
Rowasa
Sulfasalazine
Ascacol
Anucort-HC
Cortenema
Cortifoam
Uceris
Budesonide
Imuran
Remicade
Entyvio

1 g qd
4 g qd
1 g qid
4.8 g qd
25 mg qd
100 mg qd
90 mg qd
2 g qd
3 g tid
150 mg qd
5 mg/kg q 8wk
300 mg q 8wk

2 (UP)
2 (UPS)
3
4
4 (UP)
5 (UPS)
5 (UPS)
5 (UPS)
8
3
3
3

1,000
1,600
90
1,100
400
340
1,200
640
4,300
50
4,000
5,000

13
26, 28, 29
30
12
29
26, 29
26
19, 22
31
32
33
24

Hydrocortisone

Budesonide
Azathioprine
Infliximab
Vedolizumab

Notes: The dose indicated is the starting dose in an average-size adult patient that can be modified depending on weight, disease activity, and response to treatment. NNT
is the inverse of absolute risk reduction. The extent and severity of UC and treatment response and duration among different study patient populations varied; therefore,
direct comparisons of efficacy and overall health care cost among the different medications have to been done in relative terms. UP and UPS, defined as disease extending
15 and 40 cm from the anal verge, respectively, are seen in approximately 50% of UC patients. Studies evaluating oral mesalamine formulations, azathioprine, infliximab, or
vedolizumab included UC patients with both left-sided colitis and pancolitis. The average price is per month, and this is charged at a hospital pharmacy in the United States.
The price reported was calculated based on the indicated dose for 1 month.
Abbreviations: NNT, number of patients needed to treat for one patient to benefit; qd, daily; qid, four times per day; tid, three times per day; UP, ulcerative proctitis; UPS,
ulcerative proctosigmoiditis; 5-ASA, 5-aminosalicylic acid; q 8wk, every 8 weeks.

infusions every 8 weeks and a loading dose24. One 300 mg
vedolizumab infusion costs $5,800, and the treatment during
the first year costs $49,000.

Conclusion
Approximately half of patients with UC have distal colitis,
causing symptoms of bloody diarrhea, tenesmus, and rectal
pain. Despite the favorable efficacy, safety, and cost profile
of topical treatments, only one in four patients with mildto-moderate distal colitis is prescribed topical therapy. In
mild-to-moderate UP or UPS, topical therapy with 5-ASA is
recommended as a first-line agent and is cost-effective over
other treatment options. Overall, mesalamine enemas can
induce clinical and endoscopic remission in three out of four
patients with minimal side effects. Advantages of topical therapy include a quicker response time and less frequent dosing
schedule than oral therapy, as well as less systemic absorption.
The choice of topical therapy is primarily guided by patient
preference as well as by the proximal extent of disease. Some
patients may achieve maximum benefit from combination of
oral and topical therapy achieving clinical improvement, as
well as an earlier response than either agent alone.25
Previous studies demonstrated that topical corticosteroids, whether hydrocortisone or budesonide, have
not proven effective for maintaining remission in distal
colitis.26,27 Recently, Sandborn et al19 demonstrated that
rectal budesonide foam is effective at inducing remission in
mild-to-moderate active UP or UPS and has better patient
tolerability/satisfaction compared to enema formulations.
Furthermore, in patients with incomplete response to topi-

Clinical and Experimental Gastroenterology 2016:9

cal or oral mesalamine, budesonide foam could be used in
conjunction to induce remission. Alternatively, budesonide
foam can be used as an adjunctive agent during acute flares
in patients with distal colitis. Overall, it is important for
physicians to understand and in turn educate patients about
the effectiveness, safety, cost, and tolerability of topical
therapies in active distal UC.
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